Pozelimab (REGN3918), a fully human IgG4 monoclonal antibody, is designed to target and bind with high affinity to both C5 and its variants, effectively inhibiting complement-mediated hemolysis. It holds potential for research into complement-mediated di
CAS Nummer:
[2096328-94-6]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten